Infliximab is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human TNF-α that inhibits the TNF-α-mediated production of IL-8 in psoriasis plaques [47]. The gene discussed is CXCL8; the disease is psoriasis.